A suite of medical image enhancement and AI diagnostic software tools will be released, deployed, and supported by a partnership between Claritas HealthTech and PwC, it was announced.

 

The majority of medical trips begin with medical imaging, which causes demand for medical imaging to rise exponentially. However, access to imaging has lagged behind for a number of reasons, including: constrained clinician bandwidth, expensive equipment or a lack thereof, high cost and short shelf life of contrast agents, to name a few. These factors have all contributed to massive backlogs globally and pose one of the biggest challenges in the healthcare sector.

 

The iRADTM and iPETTM image enhancement and reconstruction software from Claritas, both of which have received US FDA clearance, offer modality-neutral and reasonably priced solutions to ease the strain on the diagnostic and medical imaging ecosystems. By enhancing MRIs, X-rays, and CTs, iRADTM can increase the accuracy of diagnoses, decrease the need for repeat scans, and improve first-time reading. With the aid of iPETTM, PET-CT/MRI acquisition may be completed much more quickly while requiring a lot less contrast medication.

 

“This collaboration with PwC will accelerate our global deployment strategy and deliver significant benefits to clinicians across practice areas.”, commented Chetan Baxi, CEO of Claritas.

 

Anthony Bruce, Global Healthcare Leader of PwC commented, “PwC works with national and local healthcare providers to deliver real, workable solutions to today’s challenges. We are always excited to work with new technologies, like Claritas, which seek to address some of the key bottlenecks in healthcare.”